CBPO - China Biologic Products Holdings, Inc.
| Previous Close | 74.68 |
| Open | 75.59 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 75.59 - 78.18 |
| 52 Week Range | 60.08 - 107.44 |
| Volume | 172,364 |
| Avg. Volume | 251,203 |
| Market Cap | 3.054B |
| Beta (3Y Monthly) | 0.57 |
| PE Ratio (TTM) | 37.85 |
| EPS (TTM) | 2.05 |
| Earnings Date | Feb 26, 2019 - Mar 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 104.24 |
Markit•19 days agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Associated Press•last month
China Biologic Products: 3Q Earnings Snapshot
On a per-share basis, the Beijing-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to 96 cents per share. The biopharmaceutical company posted revenue of $119.1 ...
- PR Newswire•last month
China Biologic Reports Financial Results for the Third Quarter of 2018
3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Di rectors Ap proves $100 ...
Markit•2 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The net inflows of $85 million over the last one-month into ETFs that hold CBPO are not among the highest of the last year and have been slowing.
- PR Newswire•2 months ago
China Biologic Products to Report Third Quarter 2018 Financial Results
BEIJING , Oct. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- GlobeNewswire•3 months ago
Research Report Identifies The Carlyle Group, China Biologic Products, Ericsson, Dover, GasLog Partners LP, and Spectra Energy Partners, LP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Sept. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•3 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding CBPO is favorable, with net inflows of $1.73 billion.
- Insider Monkey•3 months ago
Is China Biologic Products Inc. (CBPO) A Good Stock To Buy? Centurium Capital Thinks So
We usually stay away from Chinese companies but we came across an interesting idea recently. Earlier this year ex-Warburg Pincus China head launched his own fund, Centurium Capital, targeting to raise up to $1.5 billion. The fund was set up to invest Chinese consumer and healthcare companies. Hui Li, also known as David Li, was a director […]
Markit•3 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $7 million over the last one-month.
- Business Wire•3 months ago
David Gao Confirms Lawsuit Against China Biologic Products to Protect Shareholders’ Best Interests
Mr. David (Xiaoying) Gao, a shareholder of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (CBPO), today confirmed that he filed a lawsuit against the Company related to its private placement of shares to a select investor group – including a private equity firm formed by Board Chairman David Li. It seeks to void and invalidate the agreements with Centurium Capital Management Ltd., CITIC Capital MB Investment Limited, Hillhouse Capital Management, Ltd. and PW Medtech.
- PR Newswire•3 months ago
China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman
"We deeply regret that Mr. David Gao, acting individually in his personal capacity, has attempted to challenge the completion of the private placement that was announced on August 24. The Company is prepared to fend off meritless lawsuits like this and will take actions to seek actual and punitive damages from Mr. Gao in connection with his ill-intended lawsuit as well as any damages caused by breaches of his employment agreement. The Company continues to believe that the private placement transaction referred to in the lawsuit is beneficial to shareholders, through the additional capital and strategic partnerships which it will result in.
Markit•4 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CBPO totaled $1.57 billion.
- Reuters•4 months ago
China Biologic rejects $3.9 bln bid from former CEO
China Biologic Products Holdings Inc rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid. The consortium, which included China Biologic's former CEO David Gao, GL Capital Group, Bank of China Group Investment Ltd and CDH Investments, said on Monday it had offered $118 per share, $8 more than the CITIC unit's bid.
- Business Wire•4 months ago
Leading Investor Group Issues Statement Following China Biologic’s Dilutive Private Placement of Shares
A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today issued the following statement following China Biologic Products Holdings, Inc.’s (“China Biologic” or the “Company”) (CBPO) decision to conduct a dilutive private placement and reject the Consortium’s non-binding proposal to acquire all of the outstanding common shares of the Company for US$118.00 per share in cash. The Consortium’s proposal represented an approximate 30% premium to China Biologic’s closing share price on August 16, 2018, the last trading day before its proposal was conveyed. “We are deeply disappointed that China Biologic's Board has rejected our compelling proposal to deliver immediate and significant value to all shareholders.
- Motley Fool•4 months ago
Here's Why China Biologic Products Stock Dropped Today
After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.
- Reuters•4 months ago
BRIEF-PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln
Aug 24 (Reuters) - PW Medtech Group Ltd: * CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE * AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 ...
- PR Newswire•4 months ago
China Biologic Announces Updates on Unsolicited Acquisition Proposals and Strategic Private Placement
BEIJING, Aug. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's board of directors (the "Board") has received a letter dated August 23, 2018 from CITIC Capital MB Investment Limited, an affiliate of CITIC Capital Holdings Limited ("CITIC"), withdrawing its preliminary non-binding proposal dated June 11, 2018, with immediate effect. The Company further announced that the Board has unanimously decided to reject the previously announced preliminary non-binding proposal dated August 17, 2018 from the consortium (the "Consortium") consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited.
- Reuters•4 months ago
Deals of the day-Mergers and acquisitions
** GlaxoSmithKline is seeking initial bids by mid-September for its India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said. ** Air Canada and its partners said that data analytics firm Aimia Inc had accepted a cash offer of C$450 million ($345 million) for the sale of its Aeroplan loyalty program. ** Mattress maker Serta Simmons Bedding LLC will merge with Tuft & Needle as the two companies look to take on stiff competition from cheaper Chinese products in the U.S. market.
- ACCESSWIRE•4 months ago
Today's Research Reports on Trending Tickers: Cronos and China Biologic Products
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / U.S. markets closed in the green on Monday as optimism over easing trade tensions and news of Pepsi Co.'s acquisition plans lifted indexes higher. The Dow ...
- PR Newswire•4 months ago
China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal
BEIJING, Aug. 21, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non-binding proposal letter from a consortium (the "Consortium") consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited to acquire all of the outstanding shares of the Company not already owned by the Consortium for US$118 per share in cash (the "Consortium Proposal"). A copy of the proposal letter from the Consortium is attached hereto as Annex A. The Company previously announced its receipt of the unsolicited, preliminary non-binding proposal letter from CCRE Holdings Limited to acquire all of the outstanding shares of the Company for US$110 per share in cash (the "CITIC Proposal").
- Reuters•4 months ago
China Biologic gets $3.9 bln offer from former CEO-led consortium
China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium of investment firms, valuing the Beijing-based company at slightly above an earlier buyout proposal ...
- Motley Fool•4 months ago
Here's Why China Biologic Products Stock Is Soaring Today
The blood plasma specialist has received a second buyout offer.
- Reuters•4 months ago
China Biologic gets $3.9 billion offer from former CEO-led consortium
(Reuters) - China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium of investment firms led by the company's former chief executive David Gao. The consortium, ...
